Ascentage Pharma Group International announced its 2026 AGM to approve director re-elections, auditor re-appointment, 20% share issuance and 10% repurchase mandates, and adoption of amended memorandum and articles enabling hybrid/electronic meetings.
Key takeaways
AGM scheduled for May 20, 2026 at Suzhou headquarters to approve key governance matters.
Dr. Wang Shaomeng, Dr. Lu Simon Dazhong, and Dr. David Sidransky proposed for re-election by rotation.
Issuance Mandate authorizes up to 20% of issued Shares (373,344,750 Shares) excluding Treasury Shares.
Repurchase Mandate permits up to 10% of issued Shares (37,333,475 Shares) excluding Treasury Shares.
Special Resolution 8 approves Third Amended Memorandum and Articles for hybrid/electronic meetings effective post-AGM.
Register closes May 15-20, 2026; proxies due by 10:00 a.m. May 18, 2026.